La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Rhinomed Performance dei guadagni passati
Il passato criteri di controllo 0/6
Rhinomed's earnings have been declining at an average annual rate of -8.2%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 27.6% per year.
Informazioni chiave
-8.2%
Tasso di crescita degli utili
12.2%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore | 31.2% |
Tasso di crescita dei ricavi | 27.6% |
Rendimento del capitale proprio | n/a |
Margine netto | -135.5% |
Ultimo aggiornamento sui guadagni | 30 Jun 2023 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year
Nov 10Is Rhinomed (ASX:RNO) Using Too Much Debt?
Mar 03Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business
Mar 01Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation
Jul 09Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation
Mar 01Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque
Jan 25How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?
Dec 20Ripartizione dei ricavi e delle spese
Come Rhinomed guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Jun 23 | 8 | -11 | 12 | 1 |
31 Mar 23 | 9 | -9 | 11 | 1 |
31 Dec 22 | 9 | -7 | 11 | 2 |
30 Sep 22 | 10 | -6 | 10 | 2 |
30 Jun 22 | 10 | -5 | 10 | 2 |
31 Mar 22 | 8 | -6 | 10 | 1 |
31 Dec 21 | 6 | -6 | 9 | 1 |
30 Sep 21 | 5 | -8 | 10 | 1 |
30 Jun 21 | 4 | -9 | 10 | 1 |
31 Mar 21 | 5 | -8 | 10 | 1 |
31 Dec 20 | 5 | -7 | 9 | 0 |
30 Sep 20 | 5 | -7 | 9 | 0 |
30 Jun 20 | 4 | -7 | 9 | 0 |
31 Mar 20 | 4 | -8 | 9 | 0 |
31 Dec 19 | 4 | -8 | 9 | 0 |
30 Sep 19 | 4 | -7 | 8 | 0 |
30 Jun 19 | 3 | -6 | 7 | 0 |
31 Mar 19 | 3 | -5 | 6 | 0 |
31 Dec 18 | 3 | -5 | 6 | 0 |
30 Sep 18 | 3 | -5 | 5 | 0 |
30 Jun 18 | 2 | -4 | 5 | 0 |
31 Mar 18 | 2 | -4 | 5 | 0 |
31 Dec 17 | 1 | -5 | 5 | 0 |
30 Sep 17 | 2 | -5 | 5 | 0 |
30 Jun 17 | 2 | -4 | 5 | 0 |
31 Mar 17 | 2 | -5 | 5 | 0 |
31 Dec 16 | 2 | -5 | 5 | 0 |
30 Sep 16 | 1 | -5 | 5 | 0 |
30 Jun 16 | 1 | -6 | 6 | 0 |
31 Mar 16 | 1 | -6 | 5 | 0 |
31 Dec 15 | 1 | -6 | 5 | 1 |
30 Sep 15 | 1 | -6 | 5 | 1 |
30 Jun 15 | 0 | -5 | 4 | 1 |
31 Mar 15 | 0 | -5 | 3 | 1 |
31 Dec 14 | 0 | -5 | 2 | 0 |
30 Sep 14 | 0 | -4 | 1 | 0 |
30 Jun 14 | 0 | -4 | 1 | 0 |
31 Mar 14 | 0 | -4 | 0 | 0 |
31 Dec 13 | 0 | -4 | 2 | 0 |
30 Sep 13 | 0 | -9 | 2 | 0 |
30 Jun 13 | 0 | -15 | 2 | 0 |
Guadagni di qualità: RNO is currently unprofitable.
Margine di profitto in crescita: RNO is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: RNO is unprofitable, and losses have increased over the past 5 years at a rate of 8.2% per year.
Accelerare la crescita: Unable to compare RNO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: RNO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendimento del capitale proprio
ROE elevato: RNO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.